{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T15:34:16Z","timestamp":1794584056863,"version":"4.9.1"},"reference-count":48,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40425-018-0474-z","type":"journal-article","created":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T07:23:46Z","timestamp":1545204226000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients"],"prefix":"10.1136","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3485-7307","authenticated-orcid":false,"given":"Christina","family":"Jensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Hargb\u00f8l","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge Marie","family":"Svane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten Asser","family":"Karsdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Willumsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,12,19]]},"reference":[{"key":"474_CR1","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372:2521\u201332 Available from: \n                    http:\/\/www.nejm.org\/doi\/abs\/10.1056\/NEJMoa1503093\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"474_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373:23\u201334 Available from: \n                    http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1504030\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"4","key":"474_CR3","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1158\/2326-6066.CIR-16-0237","volume":"5","author":"G Velasco De","year":"2017","unstructured":"De Velasco G, Je Y, Boss\u00e9 D, Awad MM, Ott PA, Moreira RB, et al. Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-L1 inhibitors in Cancer patients. Cancer Immunol Res. 2017;5(4):312\u20138.","journal-title":"Cancer Immunol Res"},{"key":"474_CR4","doi-asserted-by":"crossref","unstructured":"Mushtaq MU, Papadas A, Pagenkopf A, Flietner E, Morrow Z. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers. J Immunother Cancer. 2018;6:1\u201314.","DOI":"10.1186\/s40425-018-0376-0"},{"key":"474_CR5","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/nri.2017.74","volume":"17","author":"M Huse","year":"2017","unstructured":"Huse M. Mechanical forces in the immune system. Nat Rev Immunol. 2017;17:679\u201390.","journal-title":"Nat Rev Immunol"},{"key":"474_CR6","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1172\/JCI45817","volume":"122","author":"H Salmon","year":"2012","unstructured":"Salmon H, Franciszkiewicz K, Damotte D, Dieu-Nosjean MC, Validire P, Trautmann A, et al. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Investig. 2012;122:899\u2013910.","journal-title":"J Clin Investig"},{"key":"474_CR7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer\u2013immune set point. Nature. 2017;541:321\u201330 Available from: \n                    http:\/\/www.nature.com\/doifinder\/10.1038\/nature21349\n                    \n                  .","journal-title":"Nature"},{"key":"474_CR8","first-page":"544","volume-title":"Nature","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. In: Nature, vol. 554; 2018. p. 544\u20138."},{"key":"474_CR9","doi-asserted-by":"crossref","unstructured":"Willumsen N, Thomsen LB, Bager CL, Jensen C, Karsdal MA. Quantification of altered tissue turnover in a liquid biopsy: a proposed precision medicine tool to assess chronic inflammation and desmoplasia associated with a pro-cancerous niche and response to immuno-therapeutic anti-tumor modalities. Cancer Immunol Immunother. 2017;67:1\u201312.","DOI":"10.1007\/s00262-017-2074-z"},{"key":"474_CR10","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/nrm3904","volume":"15","author":"C Bonnans","year":"2014","unstructured":"Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol. 2014;15:786\u2013801 Available from: \n                    http:\/\/www.nature.com\/doifinder\/10.1038\/nrm3904\n                    \n                  .","journal-title":"Nat Rev Mol Cell Biol"},{"key":"474_CR11","doi-asserted-by":"crossref","unstructured":"Ziani L, Safta-Saadoun TB, Gourbeix J, Cavalcanti A, Robert C, Favre G, et al. Melanoma-associated fibroblasts decrease tumor cell susceptibility to NK cell-mediated killing through matrix-metalloproteinases secretion. Oncotarget. 2017;8:19780\u201394. Available from:\u00a0 \n                    https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5386721\/\n                    \n                  .","DOI":"10.18632\/oncotarget.15540"},{"key":"474_CR12","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.molimm.2011.09.006","volume":"49","author":"TP Rygiel","year":"2011","unstructured":"Rygiel TP, Stolte EH, de Ruiter T, van de Weijer ML, Meyaard L. Tumor-expressed collagens can modulate immune cell function through the inhibitory collagen receptor LAIR-1. Mol Immunol. 2011;49:402\u20136.","journal-title":"Mol Immunol"},{"key":"474_CR13","volume-title":"Collagen fragments modulate innate immunity. Experimental biology and medicine (Maywood, NJ)","author":"AH Thomas","year":"2007","unstructured":"Thomas AH, Edelman ER, Stultz CM. Collagen fragments modulate innate immunity. Experimental biology and medicine (Maywood, NJ); 2007."},{"key":"474_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.addr.2017.07.014","volume":"121","author":"MA Karsdal","year":"2017","unstructured":"Karsdal MA, Nielsen SH, Leeming DJ, Langholm LL, Nielsen MJ, Manon-Jensen T, et al. The good and the bad collagens of fibrosis - their role in signaling and organ function. Adv Drug Deliv Rev. 2017;121:43\u201356.","journal-title":"Adv Drug Deliv Rev"},{"key":"474_CR15","first-page":"2524","volume":"10","author":"W Cheng","year":"2011","unstructured":"Cheng W, Yan-hua R, Fang-gang N, Guo-an Z. The content and ratio of type I and III collagen in skin differ with age and injury. Afr J Biotechnol. 2011;10:2524\u20139.","journal-title":"Afr J Biotechnol"},{"key":"474_CR16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0378-5122(96)01066-3","volume":"25","author":"F V\u00e1zquez","year":"1996","unstructured":"V\u00e1zquez F, Palacios S, Alema\u00f1 N, Guerrero F. Changes of the basement membrane and type IV collagen in human skin during aging. Maturitas. 1996;25:209\u201315.","journal-title":"Maturitas"},{"key":"474_CR17","first-page":"303","volume":"5","author":"MJ Nielsen","year":"2013","unstructured":"Nielsen MJ, Nedergaard AF, Sun S, Veidal SS, Larsen L, Zheng Q, et al. The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters. Am J Transl Res. 2013;5:303\u201315.","journal-title":"Am J Transl Res"},{"key":"474_CR18","doi-asserted-by":"publisher","first-page":"30599","DOI":"10.1038\/srep30599","volume":"6","author":"SN Kehlet","year":"2016","unstructured":"Kehlet SN, Sanz-Pamplona R, Brix S, Leeming DJ, Karsdal MA, Moreno V. Excessive collagen turnover products are released during colorectal cancer progression and elevated in serum from metastatic colorectal cancer patients. Sci Rep. 2016;6:30599 Available from: \n                    http:\/\/www.nature.com\/articles\/srep30599\n                    \n                  .","journal-title":"Sci Rep"},{"issue":"11","key":"474_CR19","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1002\/ijc.31627","volume":"143","author":"A Lipton","year":"2018","unstructured":"Lipton A, Leitzel K, Ali SM, Polimera HV, Nagabhairu V, Marks E, et al. High turnover of extracellular matrix reflected by specific protein fragments measured in serum is associated with poor outcomes in two metastatic breast cancer cohorts. Int J Cancer. 2018;143(11):3027\u201334.","journal-title":"Int J Cancer"},{"key":"474_CR20","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3233\/CBM-150520","volume":"15","author":"CL Bager","year":"2015","unstructured":"Bager CL, Willumsen N, Leeming DJ, Smith V, Karsdal MA, Dornan D, et al. Collagen degradation products measured in serum can separate ovarian and breast cancer patients from healthy controls: a preliminary study. Cancer Biomarkers. 2015;15:783\u20138.","journal-title":"Cancer Biomarkers"},{"key":"474_CR21","unstructured":"Bay-jensen AC, Guo X, Mortensen JH, Karsdal MA. VICM is a novel biomarker of macrophage activity evaluated in a phase IIb clinical trial of Mavrilimumab. Arthritis Rheumatol. 2015;67(suppl 10)."},{"key":"474_CR22","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1002\/cam4.303","volume":"3","author":"N Willumsen","year":"2014","unstructured":"Willumsen N, Bager CL, Leeming DJ, Smith V, Christiansen C, Karsdal MA, et al. Serum biomarkers reflecting specific tumor tissue remodeling processes are valuable diagnostic tools for lung cancer. Cancer Med. 2014;3:1136\u201345.","journal-title":"Cancer Med"},{"issue":"3","key":"474_CR23","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.3390\/cancers6031670","volume":"6","author":"T Chanmee","year":"2014","unstructured":"Chanmee T, Ontong P, Konno K, Itano N. Tumor-associated macrophages as major players in the tumor microenvironment. Cancers. 2014;6(3):1670\u201390.","journal-title":"Cancers"},{"key":"474_CR24","doi-asserted-by":"crossref","unstructured":"Bjoern J, Juul Nitschke N, Zeeberg Iversen T, Schmidt H, Fode K, Svane IM. Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab. Oncoimmunology. 2016;5:\u200be1100788.","DOI":"10.1080\/2162402X.2015.1100788"},{"key":"474_CR25","doi-asserted-by":"crossref","unstructured":"Leeming D, He Y, Veidal S, Nguyen Q, Larsen D, Koizumi M, et al. A novel marker for assessment of liver matrix remodeling: An enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M). Biomarkers. 2011;16:616\u201328. Available from: \n                    https:\/\/www.tandfonline.com\/doi\/abs\/10.3109\/1354750X.2011.620628?journalCode=ibmk20\n                    \n                  .","DOI":"10.3109\/1354750X.2011.620628"},{"key":"474_CR26","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.clinbiochem.2010.03.012","volume":"43","author":"N Barascuk","year":"2010","unstructured":"Barascuk N, Veidal SS, Larsen L, Larsen DV, Larsen MR, Wang J, et al. A novel assay for extracellular matrix remodeling associated with liver fibrosis: an enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin Biochem. 2010;43:899\u2013904.","journal-title":"Clin Biochem"},{"issue":"12","key":"474_CR27","doi-asserted-by":"publisher","first-page":"e84934","DOI":"10.1371\/journal.pone.0084934","volume":"8","author":"JM Sand","year":"2013","unstructured":"Sand JM, Larsen L, Hogaboam C, Martinez F, Han M, Larsen MR, et al. MMP mediated degradation of type IV collagen alpha 1 and alpha 3 chains reflects basement membrane remodeling in experimental and clinical fibrosis - validation of two novel biomarker assays. PLoS One. 2013;8(12):e84934.","journal-title":"PLoS One"},{"key":"474_CR28","first-page":"403","volume":"4","author":"E Vassiliadis","year":"2012","unstructured":"Vassiliadis E, Oliveira CP, Alvares-da-Silva MR, Zhang C, Carrilho FJ, Stefano JT, et al. Circulating levels of citrullinated and MMP-degraded vimentin (VICM) in liver fibrosis related pathology. Am J Transl Res. 2012;4:403\u201314.","journal-title":"Am J Transl Res"},{"key":"474_CR29","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1126\/science.aad0095","volume":"350","author":"EM Allen Van","year":"2015","unstructured":"Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350:207\u201311 Available from: \n                    http:\/\/www.sciencemag.org\/cgi\/doi\/10.1126\/science.aad0095\n                    \n                  .","journal-title":"Science"},{"key":"474_CR30","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","volume":"14","author":"SP Patel","year":"2015","unstructured":"Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14:847\u201356 Available from: \n                    http:\/\/mct.aacrjournals.org\/content\/14\/4\/847.long\n                    \n                  .","journal-title":"Mol Cancer Ther"},{"key":"474_CR31","doi-asserted-by":"crossref","unstructured":"Najjar YG, Ding F, Lin Y, VanderWeele R, Butterfield LH, Tarhini AA. Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab. J Transl Med. 2017;15:39 Available from: \n                    https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5319167\/\n                    \n                  .","DOI":"10.1186\/s12967-017-1140-9"},{"issue":"1","key":"474_CR32","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/s41467-017-00608-2","volume":"8","author":"N Jacquelot","year":"2017","unstructured":"Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Tern\u00e8s N, Jegou S, et al. Predictors of responses to immune checkpoint blockade in advanced melanoma. Nat Commun. 2017;8(1):592.","journal-title":"Nat Commun"},{"key":"474_CR33","doi-asserted-by":"crossref","unstructured":"Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med. 2011;9:204. Available from:\u00a0\n                    https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/1479-5876-9-204\n                    \n                  .","DOI":"10.1186\/1479-5876-9-204"},{"key":"474_CR34","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1200\/JCO.1999.17.6.1891","volume":"17","author":"M Deichmann","year":"1999","unstructured":"Deichmann M, Benner A, Bock M, J\u00e4ckel A, Uhl K, Waldmann V, et al. S100-beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American joint committee on Cancer stage IV melanoma. J Clin Oncol. 1999;17:1891\u20136.","journal-title":"J Clin Oncol"},{"key":"474_CR35","doi-asserted-by":"crossref","unstructured":"Kelderman S, Heemskerk B, van Tinteren H, van den Brom RRH, Hospers GAP, van den Eertwegh AJM, et al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother. 2014; Available from: \n                    http:\/\/link.springer.com\/10.1007\/s00262-014-1528-9\n                    \n                  .","DOI":"10.1007\/s00262-014-1528-9"},{"key":"474_CR36","doi-asserted-by":"publisher","first-page":"e000321","DOI":"10.1136\/rmdopen-2016-000321","volume":"2","author":"LC Cappelli","year":"2016","unstructured":"Cappelli LC, Shah AA, Bingham CO. Cancer immunotherapy-induced rheumatic diseases emerge as new clinical entities. RMD Open. 2016;2:e000321 Available from: \n                    http:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2016-000321\n                    \n                  .","journal-title":"RMD Open"},{"issue":"1","key":"474_CR37","doi-asserted-by":"publisher","first-page":"e54504","DOI":"10.1371\/journal.pone.0054504","volume":"8","author":"AC Bay-Jensen","year":"2013","unstructured":"Bay-Jensen AC, Wichuk S, Byrjalsen I, Leeming DJ, Morency N, Christiansen C, et al. Circulating protein fragments of cartilage and connective tissue degradation are diagnostic and prognostic markers of rheumatoid arthritis and ankylosing spondylitis. PLoS One. 2013;8(1):e54504.","journal-title":"PLoS One"},{"key":"474_CR38","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348:74\u201380 Available from: \n                    http:\/\/www.sciencemag.org\/cgi\/doi\/10.1126\/science.aaa6204\n                    \n                  .","journal-title":"Science"},{"key":"474_CR39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1741-7015-6-11","volume":"6","author":"PP Provenzano","year":"2008","unstructured":"Provenzano PP, Inman DR, Eliceiri KW, Knittel JG, Yan L, Rueden CT, et al. Collagen density promotes mammary tumor initiation and progression. BMC Med. 2008;6:11 Available from: \n                    http:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/1741-7015-6-11\n                    \n                  .","journal-title":"BMC Med"},{"key":"474_CR40","doi-asserted-by":"publisher","first-page":"12030","DOI":"10.1200\/JCO.2018.36.15_suppl.12030","volume":"36","author":"S Wang","year":"2018","unstructured":"Wang S, Willumsen N, Bager C, Karsdal MA, Chondros D, Taverna D. Extracellular matrix (ECM) circulating peptide biomarkers as potential predictors of survival in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (mPDA) receiving pegvorhyaluronidase alfa (PEGPH20), nab-paclitaxel (A), and gemcita. J Clin Oncol. 2018;36:12030 Available from: \n                    http:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2018.36.15_suppl.12030\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"474_CR41","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1242\/dmm.004077","volume":"4","author":"TR Cox","year":"2011","unstructured":"Cox TR, Erler JT. Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. Dis Model Mech. 2011;4:165\u201378 Available from: \n                    http:\/\/dmm.biologists.org\/cgi\/doi\/10.1242\/dmm.004077\n                    \n                  .","journal-title":"Dis Model Mech"},{"key":"474_CR42","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fphar.2016.00011","volume":"7","author":"S Ricard-Blum","year":"2016","unstructured":"Ricard-Blum S, Vallet SD. Matricryptins network with matricellular receptors at the surface of endothelial and tumor cells. Front Pharmacol. 2016;7:11.","journal-title":"Front Pharmacol"},{"key":"474_CR43","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1084\/jem.20052554","volume":"203","author":"RJ Lebbink","year":"2006","unstructured":"Lebbink RJ, de Ruiter T, Adelmeijer J, Brenkman AB, van Helvoort JM, Koch M, et al. Collagens are functional, high affinity ligands for the inhibitory immune receptor LAIR-1. J Exp Med. 2006;203:1419\u201325 Available from: \n                    http:\/\/www.jem.org\/lookup\/doi\/10.1084\/jem.20052554\n                    \n                  .","journal-title":"J Exp Med"},{"key":"474_CR44","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.15252\/embj.201490147","volume":"34","author":"N Antonio","year":"2015","unstructured":"Antonio N, Bonnelykke-Behrndtz ML, Ward LC, Collin J, Christensen IJ, Steiniche T, et al. The wound inflammatory response exacerbates growth of pre-neoplastic cells and progression to cancer. EMBO J. 2015;34:2219\u201336 Available from: \n                    http:\/\/emboj.embopress.org\/cgi\/doi\/10.15252\/embj.201490147\n                    \n                  .","journal-title":"EMBO J"},{"key":"474_CR45","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1200\/JCO.2006.09.0274","volume":"25","author":"H Schmidt","year":"2007","unstructured":"Schmidt H, Suciu S, Punt CJA, Gore M, Kruit W, Patel P, et al. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American joint committee on Cancer stage IV melanoma: results of the EORTC 18951 biochemotherapy trial. J Clin Oncol. 2007;25:1562\u20139.","journal-title":"J Clin Oncol"},{"key":"474_CR46","doi-asserted-by":"publisher","first-page":"5453","DOI":"10.1158\/1078-0432.CCR-15-0676","volume":"21","author":"C Gebhardt","year":"2015","unstructured":"Gebhardt C, Sevko A, Jiang H, Lichtenberger R, Reith M, Tarnanidis K, et al. Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with Ipilimumab. Clin Cancer Res. 2015;21:5453\u20139 Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26289067\n                    \n                  .","journal-title":"Clin Cancer Res"},{"issue":"6-7","key":"474_CR47","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.biocel.2007.12.005","volume":"40","author":"TL Adair-Kirk","year":"2008","unstructured":"Adair-Kirk TL, Senior RM. Fragments of extracellular matrix as mediators of inflammation. Int J Biochem Cell Biol. 2008;40(6-7):1101\u201310.","journal-title":"Int J Biochem Cell Biol"},{"key":"474_CR48","doi-asserted-by":"publisher","first-page":"6140","DOI":"10.1073\/pnas.1417320112","volume":"112","author":"E Romano","year":"2015","unstructured":"Romano E, Kusio-Kobialka M, Foukas PG, Baumgaertner P, Meyer C, Ballabeni P, et al. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci U S A. 2015;112:6140\u20135 Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25918390\n                    \n                  .","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0474-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-018-0474-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0474-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T13:43:19Z","timestamp":1601041399000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-018-0474-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["474"],"URL":"https:\/\/doi.org\/10.1186\/s40425-018-0474-z","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"27 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ethics Committee for The Capital Region of Denmark (H-2-2012-058) in compliance with the Helsinki Declaration of 1975. Informed consent was obtained from all individual participants included in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MAK and NW are employed at Nordic Bioscience A\/S, which is a company involved in discovery and development of biochemical biomarkers. MAK owns stocks at Nordic Bioscience.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"152"}}